[MeMed in Business Wire] MeMed BV Proven to Optimize Antibiotic Use, Outperform Standard Care, and Cut Costs in New Studies

ANDOVER, Mass. & HAIFA, Israel–(BUSINESS WIRE)–MeMed, a leader in host-response diagnostics, today announced the publication of three new peer-reviewed studies, reinforcing the real-world clinical and economic impact of MeMed BV, its flagship diagnostic for differentiating between bacterial and viral infections. Conducted across multiple centers in the U.S., Europe, and the U.K., and involving thousands of patients, these independent studies highlight distinct aspects of MeMed BV’s impact, including better antibiotic stewardship, superior performance over the standard of care, and reduced healthcare costs.

Read more here.